R. Nayar

The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering.

D. Sutherland, L. Anderson, M. Keeney, 1996, Journal of hematotherapy.

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

S. Baruchel, R. Kerbel, Y. Shaked, 2006, Clinical Cancer Research.

Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma

S. Baruchel, R. Goldsby, K. Janeway, 2012, Pediatric blood & cancer.

Current status of CD34+ cell analysis by flow cytometry: The ISHAGE guidelines

D. Sutherland, L. Anderson, M. Keeney, 1997 .

Prolonged survival in pyruvate carboxylase deficiency: lack of correlation with enzyme activity in cultured fibroblasts.

N. Rifai, R. Nayar, H. Stern, 1995, Clinical biochemistry.

Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering.

D. Sutherland, M. Keeney, R. Nayar, 1998, Cytometry.

Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide.

S. Baruchel, R. Kerbel, Y. Shaked, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.